Abiopharma

🔍 Earnest Frederick Hume (Executive)

Company: VISTA GOLD CORP (VGZ)

Report Date: 2026-03-13

Detailed Transactions and Holdings:

• Acquired 38,668 shares of Common Shares (Direct)
  Date: 2026-03-13 | Code: M | equity_swap_involved: false | shares_owned_after: 2,189,207.00 | transaction_form_type: 4
• Acquired 477,667 shares of Common Shares (Direct)
  Date: 2026-03-13 | Code: M | equity_swap_involved: false | shares_owned_after: 2,666,874.00 | transaction_form_type: 4
• Acquired 32,334 shares of Common Shares (Direct)
  Date: 2026-03-13 | Code: M | equity_swap_involved: false | shares_owned_after: 2,699,208.00 | transaction_form_type: 4
• Sold 242,200 shares of Common Shares at $2.06 per share (Direct)
  Date: 2026-03-13 | Code: F | equity_swap_involved: false | shares_owned_after: 2,457,008.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 38,668 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-13 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 477,667 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-13 | Code: M | equity_swap_involved: false | shares_owned_after: 59,666.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Sold 32,334 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-13 | Code: M | equity_swap_involved: false | shares_owned_after: 291,666.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5
• Acquired 318,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-13 | Code: A | equity_swap_involved: false | shares_owned_after: 318,000.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
• F2: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs reported in Table II.
• F3: Represents grant of 387,000 RSUs on March 5, 2023, which vest as follows: 116,000 over a 36-months period (1/3 at 12 months, 1/3 at 24 months and 1/3 at 36 months), subject to the reporting person's continuing service as an officer of the Issuer; and 271,000 two years following the grant date, contingent on share price performance criteria for the Issuer's common shares during the 2-year vesting period. Settlement of vested RSUs will occur as soon as administratively feasible following the vesting date
• F4: Represents grant of 597,000 RSUs on February 26, 2024, which vest as follows: 179,000 over a 36-month period (1/3 at 12 months, 1/3 at 24 months and 1/3 at 36 months), subject to the reporting person's continuing service as an officer of the Issuer; and 418,000 two years following the grant date, contingent on share price performance criteria for the Issuer's common shares during the 2-year vesting period. Settlement of vested RSUs will occur as soon as administratively feasible following the vesting date.
• F5: Represents grant of 324,000 RSUs on March 4, 2025, which vest as follows: 97,000 over a 36-month period (1/3 at 12 months, 1/3 at 24 months, and 1/3 at 36 months), subject to the reporting person's continuing service as an officer of the Issuer; and 227,000 two years following the grant date, contingent on share price performance criteria for the Issuer's common shares during the 2-year vesting period. Settlement of vested RSUs will occur as soon as administratively feasible following the vesting date
• F6: The RSUs vest as follows: 84,000 on 3/13/2027, subject to performance criteria; 117,000 on 3/13/2029, contingent on share price performance criteria for the Issuer's common shares during the 3-year vesting period; and 117,000 on 3/13/2029, subject to performance criteria. Settlement of vested RSUs will occur as soon as administratively feasible following the vesting date.